US Pharma MarketingThe post XBiotech to commence V-SPINE trial enrolment for vilamakitug appeared first on Clinical Trials Arena.
XBiotech to commence V-SPINE trial enrolment for vilamakitug
XBiotech is set to proceed with patient enrolment for the V-SPINE Phase II trial to assess the safety and efficacy of vilamakitug in adults with active axial spondyloarthritis. The trial will randomise 150 adults with active axial spondyloarthritis to receive 400mg vilamakitug or placebo. Vilamakitug is a monoclonal antibody targeting IL-1α, involved in spondyloarthritis-related inflammation and bone resorption. Credit: Premreuthai/Shutterstock.com. XBiotech is set to go ahead with patient enrolment for the V-SPINE (PT064) Phase II clinical trial to assess the safety and efficacy of vilamakitug in adults with active axial spondyloarthritis. This move comes following the clearance of the company’s…
XBiotech is set to proceed with patient enrolment for the V-SPINE Phase II trial to assess the safety and efficacy of vilamakitug in adults with active axial spondyloarthritis.
Source: Clinical Trials Arena